Abstract

Antiaris toxicaria (Moraceae) was evaluated for anticonvulsant activity in rodents. Animal models used include maximal electroshock test (MEST); pentylenetetrazole-induced (PTZ) convulsions; picrotoxin-induced (PCT) convulsions; strychnine- (STR-) and 4-aminopyridine-induced convulsions. Increase in latency to seizures as well as reduction in duration and frequency of seizures indicated anticonvulsant activity. The extract was more effective in all models used except the maximal electroshock test and strychnine-induced convulsions. Antiaris toxicaria aqueous extract (200, 400, and 800 mg kg−1) significantly (P < 0.05 − 0.01) shortened the duration of convulsions in PTZ- and PCT-induced seizures. Delay in the onset of convulsions in the two tests was significant (P < 0.001). Reduction in the frequency of seizures was also significant (P < 0.05 − 0.001) in both tests. Antiaris further delayed the onset of seizures in 4-aminopyridine model while producing 75% protection against death in mice. Diazepam (0.1, 0.3, and 1 mg kg−1), carbamazepine (3, 10, and 30 mg kg−1), and sodium valproate (100–400 mg kg−1) were used as reference anticonvulsant drugs for various models. Flumazenil blocked the effect of the extract in the PTZ test significantly suggesting that Antiaris toxicaria may be acting by enhancing the effects of the GABAergic system. Antiaris toxicaria aqueous extract therefore possesses anticonvulsant activity.

Highlights

  • The plant Antiaris toxicaria is an indigenous plant common in Ghanaian forests

  • Filtrate was oven-dried to obtain a yield of 23.40% w/w of Antiaris toxicaria aqueous extract (AAE)

  • AAE (200– 800 mg kg−1) produced a significant (P = 0.0021; F3,16 = 7.671; Figure 1(a)) dose-dependent increase in time taken to the onset of clonic seizures

Read more

Summary

Introduction

The plant Antiaris toxicaria (family Moraceae) is an indigenous plant common in Ghanaian forests. It is known locally as “foto” or “kyenkyen” in Akan and the bark cloth tree in English [1]. Available antiepileptic drugs (AEDs) have debilitating adverse effects on cognition and behaviour [3]. These adverse effects are commonly and consistently observed with barbiturates, benzodiazepines, and topiramate [4, 5]. This problem is further compounded by polypharmacy which characterizes treatment of epilepsy. These problems are known to prevail more in developing countries due to lack of facilities for proper diagnosis and treatment along with monitoring of AED serum levels [6, 7]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call